Relationships of genetic polymorphisms in CYP3A5 and UGT1A1 with plasma bictegravir concentrations and subjective adverse symptoms in Japanese patients with HIV-1 infection
Journal of Antimicrobial Chemotherapy · 06.10.2026 · 81 (11)
DOI: 10.1093/jac/dkag378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 02.11.2026. Verfasst von Hiroki Yagura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Medicine for HIV Infection, Institute for Clinical Research, NHO Osaka National Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Anti-HIV Agents, Cytochrome P-450 CYP3A, Glucuronosyltransferase, Heterocyclic Compounds, 4 or More Rings. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Health Labour Sciences Research.
Abstract (Originalsprache)
Objectives
Bictegravir is primarily metabolized by cytochrome P450 (CYP) 3A and UDP-glucuronosyltransferase (UGT) 1A1, both of which show genetic polymorphisms. We investigated the relationships of CYP3A5 and UGT1A1 genetic polymorphisms with plasma BIC concentrations and the occurrence of subjective adverse symptoms. Patients and methods The presence of the CYP3A5*3, UGT1A1*6 and UGT1A1*28 alleles was determined in 110 patients. Blood samples were collected at a single time point from each patient on or after Day 14 of administration for the measurement of plasma bictegravir concentration. Associations between these genetic variants, plasma bictegravir concentrations and subjective adverse symptoms within 24 weeks after the initiation of bictegravir were analysed.
Results
Allele frequencies of CYP3A5*3, UGT1A1*6 and UGT1A1*28 were 78%, 13% and 14%, respectively. Linear regression analysis demonstrated higher plasma bictegravir concentrations in patients with homozygous CYP3A5*3 variants and in those with homozygous or compound heterozygous UGT1A1 variants (*6/*6, *28/*28 or *6/*28). Trough plasma bictegravir concentrations (n = 65, 20–27 h post-dose) were 18% and 69% higher, respectively, in these groups (P = 0.041; P = 0.017). Multiple regression analysis showed that these genetic polymorphisms independently and significantly contributed to variability in plasma bictegravir concentrations. Subjective adverse symptoms were observed in 62 patients (56%), with increased appetite being the most frequent symptom (23 patients, 21%). Homozygous UGT1A1*6, compound heterozygous *6/*28 and homozygous *28 variants independently correlated with the occurrence of increased appetite (P = 0.0303).
Conclusions
UGT1A1 genetic polymorphisms were considered to independently affect plasma bictegravir exposure, whereas CYP3A5 might have a greater impact on BIC exposure when combined with UGT1A1 genetic variants. These findings suggest the need to assess both CYP3A5 and UGT1A1 genetic polymorphisms when evaluating the effects of drug-metabolizing enzymes on bictegravir concentrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Advanced Medicine for HIV Infection, Institute for Clinical Research, NHO Osaka National Hospital, Osaka, Japan.
- Department of Pharmacy, NHO Osaka National Hospital, Osaka, Japan.
- AIDS Medical Center, NHO Osaka National Hospital, Osaka, Japan.
- Department of Microbiology and Infection Control, Faculty and Graduate School of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, Osaka, Japan.
ORCID-Profile: Hiroki Yagura
Förderung
- Health Labour Sciences Research
Zitieren
APA
Yagura, H., Hisari, A., Nakauchi, T., Fujiwara, A., Hirota, K., Ueji, T., Nishida, Y., Uehira, T., Shirasaka, T., Komano, J. A., & Watanabe, D. (2026). Relationships of genetic polymorphisms in CYP3A5 and UGT1A1 with plasma bictegravir concentrations and subjective adverse symptoms in Japanese patients with HIV-1 infection. Journal of Antimicrobial Chemotherapy, 81(11). https://doi.org/10.1093/jac/dkag378
Vancouver
Yagura H, Hisari A, Nakauchi T, Fujiwara A, Hirota K, Ueji T, et al. Relationships of genetic polymorphisms in CYP3A5 and UGT1A1 with plasma bictegravir concentrations and subjective adverse symptoms in Japanese patients with HIV-1 infection. Journal of Antimicrobial Chemotherapy. 2026;81(11). doi:10.1093/jac/dkag378
BibTeX
@article{Yagura2026,
author = {Yagura, Hiroki and Hisari, Ayumi and Nakauchi, Takao and Fujiwara, Ayano and Hirota, Kazuyuki and Ueji, Takashi and Nishida, Yasuharu and Uehira, Tomoko and Shirasaka, Takuma and Komano, Jun A and Watanabe, Dai},
title = {Relationships of genetic polymorphisms in CYP3A5 and UGT1A1 with plasma bictegravir concentrations and subjective adverse symptoms in Japanese patients with HIV-1 infection},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {11},
doi = {10.1093/jac/dkag378}
}
EUVIMED